Breast Cancer and ASCO 2022

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page
3:01
Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer
Thomas Meyskens • 30 May 2022
4:29
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Thomas Meyskens • 30 May 2022
2:35
AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer
Thomas Meyskens • 30 May 2022
1:08
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
Thomas Meyskens • 30 May 2022
0:52
Patient eligibility in the AMEERA-6 trial of amcenestrant
Thomas Meyskens • 30 May 2022
1:22
Advancing cancer therapeutics for brain metastases
Bently Doonan • 14 Jun 2022
4:52
3-year DFS in randomized trials of chemotherapy and HER2-targeted therapy
Abhenil Mittal • 6 Jun 2022
0:54
Breast cancer highlights at ASCO 2022
Philippe Georges Aftimos • 5 Jun 2022
2:06
Association of 80 gene signature reclassification with neoadjuvant treatment response in BC
Pat W. Whitworth • 6 Jun 2022
1:02
Key takeaways from ASCO 2022
Pat W. Whitworth • 6 Jun 2022
2:01
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
Erika Hamilton • 10 Jun 2022
0:55
HER2CLIMB-05: tucatinib with trastuzumab and pertuzumab as maintenance therapy for HER2+ mBC
Erika Hamilton • 10 Jun 2022
0:59
Sequencing HER2-targeted therapies in breast cancer
Erika Hamilton • 10 Jun 2022
1:46
Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBC
Lajos Pusztai • 6 Jun 2022
0:56
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
Lajos Pusztai • 6 Jun 2022
1:13
Predictive markers of response to durvalumab w/nab-paclitaxel + doxorubicin/cyclophosphamide in TNBC
Lajos Pusztai • 6 Jun 2022

The Breast Cancer Channel on VJOncology is supported by Gilead.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Breast Cancer Channel, please contact us.
The content of VJOncology is intended for healthcare professionals